NASDAQ ยท Price History

Vicore Pharma Holding AB (VCRE) Price History & Returns

$8.82 NASDAQ: VCRE Market Cap $2.48B

How Vicore Pharma Holding AB (VCRE) has performed, year by year and over each trailing period. Price history only โ€” total return to a shareholder would also include dividends.

The share price of $8.82 sits 9% of the way up a 52-week range of $7.88 to $17.80; 50.4% below the 52-week high; below its 50-day moving average of $10.99; below its 200-day average of $11.39; a beta of 0.15 means it has historically moved less than the market.

Total return

Price change over each trailing period, not annualised.

PeriodReturn
3 months-36.0%
6 months+0.0%
1 year+0.0%
3 years+0.0%
5 years+0.0%
10 years+0.0%

Monthly closing prices

The last 4 months, newest first. 0 of 3 months closed higher than the month before. Each figure is the last close in that month.

MonthCloseChange
October 2026$9.38-1.5%
September 2026$9.52-13.8%
August 2026$11.04-3.2%
July 2026$11.40โ€”

Vicore Pharma Holding AB (VCRE) price history โ€” frequently asked questions

How has Vicore Pharma Holding AB performed over the last year?

Vicore Pharma Holding AB (VCRE) has risen 0.0% over the last twelve months, measured on price alone.

What is Vicore Pharma Holding AB's five-year return?

Over five years the VCRE share price has gained 0.0%, excluding dividends.

What is Vicore Pharma Holding AB's 52-week range?

Over the last year Vicore Pharma Holding AB (VCRE) has traded between $7.88 and $17.80.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.